Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis

NCT06549231 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

102

Enrollment

OTHER

Sponsor class

Conditions

Interstitial Lung Disease With Systemic Sclerosis

Interventions

DRUG: Rituximab
DRUG: Placebo

Sponsor

University Hospital, Tours